

Claims:

1.-27. (cancelled)

28. (previously presented) A vaccine comprising an immunogenically effective amount of a Minute virus of canine (MVC, also known as Canine Parvovirus-1 (CPV-1)) antigen.

29. (previously presented) The vaccine of claim 28 further comprising at least one additional antigen selected from the group consisting of a canine herpesvirus (CHV) antigen, a canine rotavirus (CRV) antigen, and a Canine Parvovirus type 2 (CPV-2) antigen.

30. (previously presented) The vaccine of claim 28 wherein the antigen is an inactivated MVC.

31. (previously presented) The vaccine of claim 29 wherein the at least one additional antigen is an inactivated virus.

32. (previously presented) The vaccine of claim 28 wherein the antigen is an attenuated live MVC.

USSN: 10/539,670
Attorney Docket: I-2002.025 US
Response to Office Action of July 20, 2007

33. (previously presented) The vaccine of claim 29 wherein the at least one additional antigen is an attenuated live virus.
34. (previously presented) A method of protecting a puppy against Minute virus of canine (MVC, also known as Canine Parvovirus-1 (CPV-1)) comprising
- i) administering a vaccine comprising an immunogenically effective amount of an MVC antigen to a pregnant bitch prior to whelp, and
 - ii) administering colostrums of the bitch to at least one puppy within about forty-eight (48) hours of whelp whereby maternal antibodies are transferred at a sufficiently high titer to protect the puppy from disease caused by MVC.
35. (previously presented) The method of claim 34, comprising administering colostrums of the bitch to at least one puppy within about 24 hours of whelp.
36. (previously presented) The method of claim 34, wherein the maternal antibodies are transferred by allowing the puppy to nurse the bitch within about forty-eight (48) hours of whelp.
37. (previously presented) The method of claim 36, wherein the maternal antibodies are transferred by allowing the puppy to nurse the bitch within about 24 hours of whelp.

38. (previously presented) The method of claim 34, wherein the MVC antigen is inactivated MVC.
39. (previously presented) The method of claim 34, wherein the MVC antigen is attenuated live MVC.
40. (previously presented) The method of claim 34, wherein the vaccine further comprises at least one additional antigen selected from the group consisting of a canine herpesvirus (CHV) antigen, a canine rotavirus (CRV) antigen, and a Canine Parvovirus type 2 (CPV-2) antigen.
41. (previously presented) The method of claim 40, wherein the at least one additional antigen is an inactivated virus.
42. (previously presented) The method of claim 40, wherein the at least one additional antigen is an attenuated live virus.